In RRMS patients, IL17 secretion from cladribine-treated cells was significantly higher at day 7 and day 14, in line with the proliferation of CD3+IL17+ and CD3+IFNγ+IL17+ cells exposed to cladribine. Here, IL17A is linked to relapsing-remitting multiple sclerosis.